Tuberculosis, Pulmonary Clinical Trial
Official title:
Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis
Background:
Drug resistant tuberculosis is a serious public health problem that threatens the health of
human life and the development of society and economy. At present, the diagnosis of
drug-resistant tuberculosis mainly depends on traditional drug susceptibility test. But it
is limited in Mycobacterium tuberculosis slow growth speed, traditional solid drug
sensitivity test usually need to 3 months to results, delay the development of drug
resistance in patients with effective treatment. Probe melting curves resistance detection
technology is the recent emergence of a new molecular biology and drug resistant
tuberculosis detection technology, probe melting curves with different fluorescent labeled
probe coverage detection specific to M.tuberculosis drug resistance determining region,
through changes in the melting point of the probe hybridization, acquire mutation
information of detection region, shorten detection time and detect nonuniform resistance.
In this study, by selecting a nationally representative in different levels of hospitals
jointly launched multi center, large sample clinical assessment, completed the comprehensive
evaluation of sensitivity, specificity and health economics of drug resistant pulmonary
tuberculosis, especially resistance to multidrug and extensively drug-resistant TB patients
detection,in order to evaluate the rapid, accurate and economic and appropriate technology
of drug resistance pulmonary tuberculosis detection.
In order to accomplish the overall goal of the project, in the framework of the overall
design, according to the principles of the core tasks are divided into four sub topics,
namely:
Sub topic 1 of the core mission is included in 3100 cases of smear positive pulmonary TB
suspicious symptoms, from which selected more than 1000 cases of drug-resistant pulmonary
tuberculosis patients, using MGIT liquid culture and drug sensitivity test as the gold
standard,evaluate the sensitivity and specificity of probe melting curves in detction of
resistance of four kinds of anti tuberculosis drug to Mycobacterium tuberculosis; Sub topic
2 core task is including at least 500 cases of culture positive pulmonary tuberculosis
patients and treatment follow-up, using MGIT liquid culture and drug sensitivity test as the
gold standard, evaluate the application value of probe melting curves for monitoring
spectrum changes of drug resistance of Mycobacterium tuberculosis during pulmonary
tuberculosis treatment.
The core mission of sub topic 3 is to project implementation of hospital as the research
site,acquire the cost-effect evaluation and analysis by comparing probe melting technology
with Mycobacterium tuberculosis MGIT liquid culture, and drug sensitivity test with xpert
MTB/RIF technology.
Sub topic 1:Probe melting curve method for the analysis of drug resistance detection
technology for detection of Mycobacterium tuberculosis resistance performance analysis.
Research methods: multi center clinical study. Research object: sputum acid fast staining
microscopy positive of pulmonary tuberculosis with suspicious symptoms.
Technical principle and operation method: see attachment.
Entry criteria:
1) during the study of all smear positive pulmonary tuberculosis with suspicious symptoms;
2) can provide 3-4ml sputum samples three times in 2 days; 3) informed consent. Exclusion
criteria: the quality of sputum specimen is not qualified (sputum sample is less than 3ml or
saliva sputum).
1. sample estimate Method and formula: according to the national tuberculosis drug
resistance in the baseline survey results, isoniazid, rifampicin, fluoroquinolones and
streptomycin anti tuberculosis drugs, fluoroquinolones resistance rate is low; using
fluoroquinolones detection estimation sample content, can meet the needs of other anti
tuberculosis drug resistance rate analysis.
2. observation index: (1) basic information: demographic data, underlying diseases, the
diagnosis and treatment of tuberculosis, epidemiological characteristics.
(2) the clinical symptoms and signs: fever, night sweats, cough, sputum and sputum, weight
loss, hemoptysis or sputum with blood, chest pain, dyspnea, fatigue, height, weight,
pulmonary rales.
(3) chest imaging (chest X-ray or CT scan): the specific description of the lesion
distribution and morphological characteristics and scoring.
(4) laboratory examination: erythrocyte sedimentation rate (ESR), blood routine test, blood
biochemistry (AST, ALT, TP, ALB, BUN, Cr and Glu), C-reactive protein (CRP).
(5) microbiological examination of sputum, sputum acid fast staining microscopy, MGIT liquid
culture and drug sensitivity detection, xpert MTB/RIF, probe melting curves technology.
95% confidence intervals, using statistical methods by chi square test and Kappa test.
sub topic 2:the follow up of diagnosis and treatment in application of Probe melting curve
method of resistance detection in patients with pulmonary tuberculosis.
Research methods: multi center clinical study. Study subjects and sample size: MGIT liquid
culture positive pulmonary tuberculosis patients in sub topic 1, to be included in at least
500 cases.
Entry criteria and exclusion criteria: the same as the research sub topic 1.
1 observation index:
1. with the clinical symptom and physical sign of diagnostic node changes: fever, night
sweats, cough, sputum and sputum, weight loss, hemoptysis or sputum with blood, chest
pain, dyspnea, fatigue, height, weight, pulmonary rales.
2. the changes of chest imaging in the follow up nodes: a detailed description of the
image.
3. with the clinical examination of diagnostic node: erythrocyte sedimentation rate (ESR),
blood routine test, blood biochemistry (AST, ALT, TP, ALB, BUN, Cr and Glu), C-reactive
protein, and so on.
4. with diagnosis node sputum microbiology examination: sputum acid fast staining
microscopy, MGIT liquid drug sensitive culture, Xpert-MTB/RIF and probe melting curves.
5. classification of outcomes:
1. effective: to complete the prescribed course of treatment, sputum culture
negative; chest X-ray absorption improvement;
2. failure: treatment for 6/8 months with smear / culture examination positive and /
or radiographic improvement;
3. non tuberculosis deaths: death due to causes other than tuberculosis;
4. tuberculosis death: death due to disease progression or complications; (E)
shedding: interruption of treatment and follow-up can not be achieved;
(f) diagnostic change: diagnosis of pulmonary tuberculosis in the treatment process.
6. the change of drug resistance spectrum (a) drug resistance spectrum change: the change
of drug resistance of Mycobacterium tuberculosis in the course of follow-up; (b) not
uniform resistance: refers to the of the results of the original probe melting curve
resistance detection technology analysis, it is found that the probe melting curve peak
spectrum chart presents the characteristics of two kinds of different genotype.
2.quality control and acceptance: the same research sub topic 1. 3 data statistics and
analysis: Probe melting curves,the molecular diagnostic technique in patients with pulmonary
tuberculosis treatment with statistical methods is the application of diagnosis in the
calculated two-sided 95% confidence interval, chi square test and kappa test.
sub topic 3:Probe melting curve technology for the cost-effect analysis in detection of
drug-resistant Mycobacterium tuberculosis.
Methods: using the cost analysis method and the questionnaire. Research object: research
project implementation hospital laboratory.
Data collection, statistics and analysis:
1 cost analysis
1. each of the implementation of the following basic data collection and data entry
software.
1. the basic costs: were collected for the implementation of the hospital basic input
costs, including laboratory housing area, housing area of the office area,
laboratory construction and renovation costs, considering the useful life of
housing, the conversion of housing cost per unit time.
2. laboratory equipment costs: all experimental equipment of the cost in purchasing
the new price to calculate and the cost should include all procurement costs
associated with, such as transportation, installation; annual collection of major
equipment maintenance / repair costs, according to the useful life of the
instrument, converted instrument unit time cost.
3. laboratory management costs: laboratory water, electricity, garbage disposal fees,
heating costs, etc.;
4. personnel costs: laboratory staff wages, including all bonuses and allowances paid
to employees; (E) cost of supplies: laboratory, including gloves, laboratory
clothing, hats, conventional reagents, such as the unit price;
(f) the above collection cost input software, as a basis for the implementation of the
basic data of the hospital;
2. selection of opportunity cost method, were three projects in the implementation of
hospital laboratory independently collected nine laboratory personnel process time, the
use of instruments, reagents, consumables and the number of consumption, accurately to
the recorded in the tables of statistics in; every collection cost shall cover high,
medium and low different sample size, average value of 3 times the amount of sample;
will collect the data and time consuming product data entry forms, different batches of
cost calculation, will each region three times the cost of taking the average value is
real-time fluorescent nucleic acid isothermal amplification detection technique for
each detection unit.
3. to analyze the prevalence rate of tuberculosis in different projects, and to calculate
the cost of tuberculosis patients in different regions.
2 acceptance survey: the design of the questionnaire, the survey of 3 projects in the
implementation of the hospital not less than 10 laboratory technicians. The questionnaire
covers the convenience of other methods, the needs of the laboratory, the application
prospects and other aspects of the content.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06084715 -
The INSTITUT Study
|
||
Terminated |
NCT03028129 -
Prevention of Tuberculosis in Prisons
|
Phase 4 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Withdrawn |
NCT03862248 -
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
|
Phase 3 | |
Completed |
NCT03271567 -
Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Active, not recruiting |
NCT04919239 -
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
|
Phase 2 | |
Active, not recruiting |
NCT03251196 -
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
|
||
Recruiting |
NCT05926466 -
BTZ-043 Dose Evaluation in Combination and Selection
|
Phase 2 | |
Recruiting |
NCT04752592 -
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Not yet recruiting |
NCT04968886 -
TuBerculosis Viability Interregional Study and Agreement on Biological Tests
|
||
Not yet recruiting |
NCT04485156 -
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
|
Phase 3 | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT01364324 -
Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
|
||
Active, not recruiting |
NCT04179500 -
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
|
Phase 2 | |
Completed |
NCT05899400 -
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
|
||
Completed |
NCT04938596 -
Airborne Preventive Measures to Reduce New TB Infections in Household Contacts
|
N/A | |
Recruiting |
NCT05455112 -
Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis
|
Phase 2 | |
Completed |
NCT03044158 -
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
|
N/A |